The combination of PD1/PD-L1 blockade with CTLA-4 inhibition has been investigated in a single-arm pilot study where a response rate of 43% was observed in patients with metastatic TNBC; on the other hand, patients with HR+ breast cancer showed no significant responses [46]. This evidence concerns the gene CD274 and breast carcinoma.